Kahn Swick & Foti is deepening its investigation into agilon health following the company’s recent announcement of a significant reduction in its profit forecasts. This development raises critical questions about agilon’s leadership and financial stability, making it essential for investors and stakeholders to stay informed.
NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has continued its investigation into agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL). On January 5, 2024, the Company disclosed that it was slashing its 2023 profit forecasts, specifically, lowering its 2023 Medical Margin expectation to “$340 million to $360 million, approximately $110 million
Source: Original Press Release
